AXSM - NASDAQ

Axsome Therapeutics, Inc.

AXSM·NASDAQ

$233.49

+5.1%

HealthcareBiotechnology

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$12.02B

EPS-3.6800

P/E Ratio-63.45

Earnings Date08/03/2026

689.80M

Assets

21%

3Y+108.0%

5Y+271.0%

10Y+1705.0%

601.51M

Total Liabilities

18%

3Y+171.0%

5Y+731.0%

10Y+3515.0%

88.30M

Total Equity

55%

3Y-19.0%

5Y-22.0%

10Y+309.0%

Axsome Therapeutics, Inc. Funding & Solvency Profile

AXSM · NASDAQ

Current Assets

Cash & Cash Equivalents322.93M

Net Receivables224.46M

Inventory27.94M

Other Current Assets13.65M

Total Current Assets589 M

Non-Current Assets

Property, Plant & Equipment20.86M

Goodwill & Intangible Assets52.56M

Long-Term Investments0.00

Other Non-Current Assets27.40M

Total Non-Current Assets48 M

Total Assets

689.80M

Financial Health Analysis

Current Ratio

1.55x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

6.81x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

210 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

85% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Axsome Therapeutics, Inc. Balance Sheet

AXSM • NASDAQ

Axsome Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	322.9M	315.4M	386.2M	200.8M	86.5M	183.9M	220M	14M	34M	36.6M	48M	2.6M	2.1M
Cash & Short-Term Investments	322.9M	315.4M	386.2M	200.8M	86.5M	183.9M	220M	14M	34M	36.6M	48M	2.6M	2.1M
Net Receivables	224.5M	142M	94.8M	37.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	224.5M	142M	94.8M	37.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	27.9M	15.7M	15.1M	4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	45.3K	148.4K	413.1K	1.2M	1.3M	1.4M	996.6K	125.9K	5.8K
Other Current Assets	13.7M	12M	8.1M	2.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7K
Total Current Assets	589M	485.1M	504.3M	245.6M	86.5M	184M	220.4M	15.2M	35.3M	38M	49M	2.7M	2.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	20.9M	6M	7.6M	1.1M	944K	1.8M	30.6K	51.8K	68.1K	100.7K	16.7K	0.0	0.0
Goodwill	12M	12M	12M	10.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	40.5M	46.9M	53.3M	59.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	52.6M	58.9M	65.3M	70M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	27.4M	18.5M	11M	14.7M	322.9K	317.4K	139.9K	112.3K	188K	112.8K	26.6K	42.6K	0.0
Total Non-Current Assets	100.8M	83.4M	84M	85.8M	1.3M	2.1M	170.5K	164.2K	256K	213.6K	43.3K	42.6K	0.0
Total Assets	689.8M	568.5M	588.2M	331.5M	87.8M	186.1M	220.5M	15.4M	35.6M	38.2M	49.1M	2.8M	2.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	65.6M	73M	40.7M	38.6M	13.1M	13.5M	10.9M	3.7M	3.4M	4.1M	1.9M	758.2K	159.3K
Accounts Payable	65.5M	72M	40.7M	38.6M	13.1M	13.5M	10.9M	3.7M	3.4M	4.1M	1.9M	758.2K	159.3K
Other Payables	101K	960K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	36.9M	117.4M	20.5M	40.3M	5.2M	8.7M	10.9M	3.8M	2.7M	2.8M	739.5K	36.4K	140.2K
Short Term Debt	73M	0.0	0.0	0.0	0.0	0.0	2.6M	3.3M	3.3M	269.2K	0.0	41.5K	3.8M
Capital Lease Obligations (Current)	0.0	3.3M	1.3M	425K	620.7K	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	960K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3M	0.0	0.0	36.4K	0.0
Other Current Liabilities	203.3M	36.5M	76.5M	17.2M	4.1M	0.0	0.0	0.0	444.3K	0.0	0.0	100.1K	0.0
Total Current Liabilities	378.8M	230.1M	138.9M	96.6M	23.1M	23.4M	24.5M	10.8M	12.2M	7.2M	2.6M	972.6K	4.1M
NON-CURRENT LIABILITIES
Long Term Debt	140.9M	180.7M	178.1M	94.3M	49.1M	48.3M	17.3M	3.6M	6.7M	9.5M	0.0	4.4M	0.0
Other Non-Current Liabilities	54.4M	91.7M	73.3M	31.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	574.9K	0.0
Total Non-Current Liabilities	222.7M	281.4M	258.4M	125.4M	49.1M	48.9M	17.3M	3.6M	6.7M	9.5M	0.0	5M	0.0
Capital Lease Obligations	27.4M	12.2M	8.3M	425K	620.7K	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	601.5M	511.5M	397.3M	221.9M	72.2M	72.3M	41.8M	14.4M	18.8M	16.6M	2.6M	6M	4.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1K
Common Stock	5K	5K	5K	4K	3.8K	3.7K	3.7K	3K	2.5K	1.9K	1.9K	1.1K	769.0
Additional Paid-In Capital	1.4B	1.2B	1B	705.9M	424.8M	392.6M	354.6M	108.5M	93.3M	69.2M	66.9M	5M	205.2K
Retained Earnings	-1.3B	-1.1B	-835.6M	-596.3M	-409.2M	-278.8M	-175.9M	-107.6M	-76.6M	-47.6M	-20.4M	-8.2M	-2.2M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.1K
Total Stockholders' Equity	88.3M	57M	191M	109.6M	15.6M	113.8M	178.7M	937.9K	16.7M	21.6M	46.4M	-3.2M	-2M
Total Equity	88.3M	57M	191M	109.6M	15.6M	113.8M	178.7M	937.9K	16.7M	21.6M	46.4M	-3.2M	-2M
SUMMARY
Total Liabilities & Equity	689.8M	568.5M	588.2M	331.5M	87.8M	186.1M	220.5M	15.4M	35.6M	38.2M	49.1M	2.8M	2.1M
Total Debt	241.3M	193M	186.4M	94.7M	49.7M	50.1M	19.9M	6.9M	9.9M	9.7M	0.0	4.5M	3.8M
Net Debt	-81.6M	-122.4M	-199.8M	-106.2M	-36.8M	-133.8M	-200M	-7.1M	-24.1M	-26.9M	-48M	1.9M	1.7M
Shares Outstanding	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640	50,412,640

SEC Filings

AXSM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 01, 2026	April 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 288 filings

Related Guides

Blog Categories

Continue your AXSM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.